Med BioGene Adopts Shareholder Rights Plan | GenomeWeb

NEW YORK (GenomeWeb News) – Canadian diagnostic developer Med BioGene announced the adoption of a shareholder rights plan.

Med BioGene said that the purpose of the rights plan is to provide sufficient time to its board and shareholders to assess any unsolicited bids to take over the company, and to allow the board to consider "value-enhancing" alternatives and entertain competing bids.

The rights plan is subject to ratification by shareholders at the company's annual meeting, to be held on Feb. 12.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.